Israel Englander Krystal Biotech, Inc. Call Options Transaction History

Millennium Management LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $520,608 - $624,376	3,400 Added 65.38%	8,600 $1.58 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $561,652 - $932,620	5,200 New	5,200 $925,000
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $400,248 - $664,632	5,100 New	5,100 $598,000
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $2.66 Million - $3.38 Million	-41,000 Reduced 80.39%	10,000 $697,000

278

24.9M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.7B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.